Clinical Hospital 'Pheophania' of State Affairs Department, Zabolotny str,, 21, Kyiv 03680, Ukraine.
EPMA J. 2013 Dec 6;4(1):24. doi: 10.1186/1878-5085-4-24.
Endometrial hyperplasia has a high risk for malignant transformation and relapses; existing mini-invasive treatments may lead to irrevocable endometrium destruction. The aims were to analyze receptor systems in endometrial hyperplasia, to evaluate the capabilities of ultrasonography, sonoelastography for diagnosis and treatment control, and to develop treatment algorithm.
We included 313 women (20-45 years), assessed into the following: group 1 (n = 112) with glandular cystic hyperplasia, group 2 (n = 98) endometrial polyps, and group 3 (n = 103) atypical hyperplasia; and 82 controls who have undergone hysteroscopy before in vitro fertilization in tubal origin infertility were also included. Patients underwent clinical examination, transvaginal ultrasound, immunohistochemical study, and hormonal therapy/hysteroresectoscopy.
In patients with glandular hyperplasia, we registered increase of endometrium estrogen receptors (75.6% in the epithelium and 30.9% in the stroma; in controls, 43.3% and 29.6%, respectively); in polyps, there was a significant estrogen receptor increase in the stroma (48.2% vs 29.6% in controls), and in atypical hyperplasia, progesterone receptors significantly increased in the stroma. Ki-67 increased (40% to 50%) in the epithelium without changes in the stroma. Ultrasound has a sensitivity of 96% and a specificity of 85% for early detection of endometrial pathology and prediction outcome of intervention, and sonoelastography has a sensitivity of 91% and a specificity of 83% for polyp diagnosis. Personalized treatment was effective in 88.8%, relapse was diagnosed in 11.2% after 6 months, and conservative treatment of atypical hyperplasia was effective in 45%: in 25.8%, ablative hysteroresectoscopy was performed, while in 22.6% with comorbidities, hystero/oophorectomies were performed.
The evaluation of receptor status with ultrasound data in patients with endometrial hyperplasia allows for a clear definition of the treatment policy, avoidance of relapse, treatment optimization, and observation of such patients.
子宫内膜增生具有恶性转化和复发的高风险;现有的微创治疗方法可能导致不可逆转的子宫内膜破坏。目的是分析子宫内膜增生中的受体系统,评估超声、超声弹性成像在诊断和治疗控制方面的能力,并制定治疗方案。
我们纳入了 313 名年龄在 20-45 岁的女性(112 名患有腺囊性增生,98 名患有子宫内膜息肉,103 名患有非典型增生)和 82 名在体外受精前因输卵管原因不孕而接受宫腔镜检查的对照组。患者接受了临床检查、经阴道超声、免疫组织化学研究和激素治疗/子宫切除术。
在腺性增生患者中,我们发现子宫内膜雌激素受体增加(上皮 75.6%,基质 30.9%;对照组分别为 43.3%和 29.6%);在息肉中,基质中的雌激素受体显著增加(48.2%比对照组的 29.6%),在非典型增生中,孕激素受体在基质中显著增加。Ki-67 在上皮细胞中增加(40%-50%),而基质中没有变化。超声对子宫内膜病变的早期检测和干预结果的预测具有 96%的敏感性和 85%的特异性,超声弹性成像对息肉的诊断具有 91%的敏感性和 83%的特异性。个性化治疗在 88.8%的患者中有效,6 个月后诊断出 11.2%的复发,对非典型增生的保守治疗有效率为 45%:25.8%的患者行消融性子宫切除术,22.6%的患者合并症而行子宫/卵巢切除术。
在子宫内膜增生患者中,根据超声数据评估受体状态可以明确治疗策略,避免复发,优化治疗,并对这些患者进行观察。